Physician profile
Mary E White
NPI 1366938649
$2,686.19
in general payments reported to CMS, 2019-2025
24 companies · $673 in 2025
The $673 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.39 · 2022: $487 · 2023: $812 · 2024: $701 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $432.46 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $293.90 | 2022 | |
| Novo Nordisk INC | $275.26 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $238.06 | 2022-2025 | |
| Glaxosmithkline, LLC. | $210.03 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $181.36 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $155.60 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $144.12 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $128.30 | 2023-2024 | Otezla, Repatha, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $77.67 | 2024-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $76.57 | 2023-2025 | Voquezna |
| Exact Sciences Corporation | $74.59 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $63.31 | 2023 | Rexulti |
| Astellas Pharma US INC | $60.36 | 2022-2024 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $59.76 | 2022-2023 | Seglentis, Livalo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $41.60 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Xeris Pharmaceuticals, INC. | $41.15 | 2022-2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $36.14 | 2024-2025 | Inspire |
| Neurocrine Biosciences, INC. | $23.14 | 2023 | Ingrezza, Ongentys |
| Verona Pharma, INC. | $15.56 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.34 | 2022 | |
| Merck Sharp & Dohme LLC | $14.74 | 2022 | |
| Boston Scientific Corporation | $13.78 | 2025 | Wavewriter Alpha Prime 16 |
| Genentech USA, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.